科学文献
我们与学术机构开展合作研究，以评估我们的管线产品。以下是发表的相关文献。
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM, Yang F, Tian X, Sun H, Zhuang SH, Ren J, Fan X, Jin J, Niu T, Chen SJ
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
Masaki Ri, Kenshi Suzuki, Tadao Ishida, Junya Kuroda, Taku Tsukamoto, Takanori Teshima, Hideki Goto, Carolyn C. Jackson, Huabin Sun, Lida Pacaud, Ei Fujikawa, Tzu-Min Yeh, Tomoyoshi Hatayama, Kensuke Aida, Yoshihiro Sunagawa, Shinsuke Iida
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study
Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Deepu Madduri, Carolyn C Jackson, William Deraedt, Katharine S Gries, John M Fastenau, Jeremiah J Trudeau, Muhammad Akram, Lida Pacaud, Andrzej Jakubowiak, Sundar Jagannath
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
Liviawati S. Wu, Yaming Su, Claire Li, Wangda Zhou, Carolyn C. Jackson, Yu-Nien Sun, Honghui Zhou
Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access
J Mikhael, J Fowler, N Shah
